Product logins

Find logins to all Clarivate products below.


Biosimilars – Access & Reimbursement – Access & Reimbursement Global Landscape

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and differences between countries can be a significant challenge. The Access & Reimbursement Landscape allows rapid assessment of key market access parameters in the United States, EU5, Japan, Canada, and key emerging markets.

Questions answered

  • Does a dedicated biosimilar pathway exist in the country of interest?
  • What types of biological products fall within the scope of biosimilar guidance?
  • What are the regulatory considerations with regard to reference-product selection?
  • Is automatic pharmacy-level substitution permitted?
  • What pricing mechanisms exist for biosimilars and their reference products?
  • Is the local government actively driving biosimilar uptake?

Key markets covered

France, Germany, Italy, Spain, United Kingdom, United States, Japan, Australia, Brazil, Canada, and China.

Key companies mentioned

  • Amgen
  • Biocon
  • Boehringer Ingelheim
  • Celltrion
  • Eli Lilly
  • Fresenius Kabi
  • Hospira
  • Merck & Co.
  • Pfizer
  • Roche
  • Samsung Bioepis
  • Sandoz
  • Viatris

Key drugs mentioned

  • Avastin
  • Alymsys
  • Aybintio
  • Basaglar
  • Benepali
  • Binocrit
  • Brenzys
  • Byooviz
  • Byvasda
  • Enbrel
  • Fulphila
  • Herceptin
  • Humira
  • Inflectra
  • Kanjinti
  • Mvasi
  • Neulasta
  • Nepexto
  • Nivestim
  • Nyvepria
  • Onbevzi
  • Ongavia
  • Releuko
  • Remicade
  • Renflexis
  • Remsima
  • Rianbi
  • Rituxan / MabThera
  • Ruxience
  • Semglee
  • Stimufend
  • Truxima
  • Udenyca
  • Vegzelma
  • Yuflyma
  • Zarzio / Zarxio
  • Zercepec
  • Zirabev

Table of contents


Related Market Assessment Reports

Report
Breast Cancer | China In-Depth | China | 2024
The breast cancer therapy market is one of the most dynamic markets in the oncology space in mainland China. Several new and emerging therapies are set to be approved for select subpopulations;…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left…
Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…
Report
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly…
Report
Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The type 2 diabetes (T2D) therapy market will expand through 2034, supported by polypharmacy and the growing use of effective branded therapies offering nonglycemic benefits. Although the loss of…